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Cell-cycle controlMitogen-activated protein kinase kinase 4 (Map2k4) is a dual speciﬁcity serin/threonine protein kinase that is
unique among all MAP2Ks in activating two different subfamilies of mitogen-activated protein kinases, the c-
Jun N-terminal kinases (JNKs) and p38 kinases. Map2k4 is essential during embryogenesis and involved in a va-
riety of physiological and pathological processes. However, studies on its role in cancer development revealed
partially conﬂicting data. In the present study, we report the identiﬁcation of a novel splice variant ofMap2k4,
Map2k4δ, with an additional exon in front of the substrate binding D-domain. Map2k4δ is expressed together
with Map2k4 in various tissues from rat, mouse and human. In PC12 cells, both splice variants control cell
cycle progression and basal apoptosis by using different signaling pathways. If expression and activation of
Map2k4 andMap2k4δ are at a certain, cell type-speciﬁc equilibrium, an appropriate cell growth is ensured. Over-
expression of one kinase disrupts the intricate balance and either results in a highly proliferative or pro-apoptotic
phenotype, partially reﬂecting the discrepancies in the literature on Map2k4 and its role in tumor development.
Our ﬁndings contribute to the understanding of previous studies and point out thatMap2k4 has not always a def-
inite function, but rather triggers a cellular reaction in concert with other modulators.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The mitogen-activated proteinkinase (MAPK) pathways initiate a
wide spectrum of cellular responses. Starting with basal cellular pro-
cesses like gene transcription or protein synthesis to highly concerted
developmental programs like proliferation, differentiation or apoptosis,
their functions are not only versatile but can also be contradictory [1–3].
All enzymes of the three-tiered MAPK signaling cascade are highly
conserved, mostly ubiquitously expressed and overlapping in their
substrates. Therefore, the speciﬁcity of their cellular effects has to be
secured by expression, cellular localization and interactions with their
targets or scaffolds. The last few years have shown that individual splice
variants of mitogen-activated protein kinases or their activators can
cause distinct and sometimes conﬂicting cellular responses [4–9].transcription factor 2; BrdU, 5-
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.de (V. Waetzig).
ights reserved.The mitogen-activated protein kinase kinase 4 (Map2k4, MKK4) is
unique among all known MAP2Ks in its ability to phosphorylate two
different MAPKs, p38 and JNK (c-Jun N-terminal kinase), respectively.
TheMap2k4 gene encodes for a dual speciﬁcity serin/thereonine protein
kinase, 399 (human; 397 formouse and rat) amino acids long and high-
ly conserved throughout evolution [10,11]. The tertiary structure of the
protein consists of three functional domains: (i) the kinase domain,
where Map2k4 is activated by the majority of MAP3Ks (mitogen-
activated protein kinase kinase kinases) by dual phosphorylation in
the S-I-A-K-T motif, (ii) a domain for versatile docking (DVD) where
upstream kinases and scaffold proteins bind to Map2k4 and (iii) a
D-domain type of docking site for binding of p38 and JNK. Indeed, stud-
ies withMap2k4−/−mice showed no obvious changes in p38 activation
but dramatic defects in JNK activation [12].
Map2k4 is involved in a variety of physiological and pathological
processes. During embryogenesis, Map2k4 plays essential roles in
hepatogenesis and brain development [13,14]. Therefore, mice with a
targeted deletion of Map2k4 die between E11.5 and E13.5 [13]. More-
over, Map2k4 is relevant in embryonic stem cell differentiation, the
immune system and the heart [15–17]. Regarding its chromosomal
locus next to the tumor suppressor p53 on chromosome 17, Map2k4
was intensively studied in tumor initiation. Indeed, studies of a wide
spectrum of primary cancers demonstrated loss-of-function mutations
in Map2k4 especially in lung and pancreatic tumors [18–22]. Further-
more, endogenous expression of Map2k4 could reduce metastasis of
prostate and ovarian tumors in mice [23,24]. In contrast, an equal
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role for Map2k4 [25–28]. For example, skin-speciﬁc Map2k4-deﬁcient
mice are resistant to carcinogen-induced tumorigenesis and injection
of Map2k4−/− pancreatic cells into mice reduced lung metastases of
the primary pancreatic tumor [29]. However, as recently pointed out it
is neither possible nor necessary to deﬁne a clear-cut role for Map2k4
as a suppressor or promoter of tumorigenesis, but more important to
understand Map2k4-dependent signaling in tumor cells [30].
In the present study, we identiﬁed a novel Map2k4 splice variant,
Map2k4δ, expressed in various tissues of rat, mouse and human and al-
ways together with Map2k4. We investigated the functional relevance
of Map2k4 and Map2k4δ in regulation of MAPK signaling in PC12
cells, a well studied cellular model system. The results reveal distinct
signaling and functional properties of bothMap2k4 splice variants lead-
ing to partially opposing cellular reactions. Our observations indicate
that the expression and activation of Map2k4 and Map2k4δ have to be
at equilibrium to control cell growth and basal apoptosis. If unbalanced,
proliferation or cell death predominate and lead to a phenotype that is
either suggestive of a pro-oncogene or a tumor-suppressor. Thus, our
ﬁndings partially explain the discrepancies between the existing studies
and also emphasize that a single molecule does not always have a deﬁ-
nite role with a deﬁnite cellular effect, but rather fulﬁlls a function in
concert with other modulators.
2. Materials and methods
2.1. Cell culture
Rat pheochromocytoma PC12 cells (DSMZ; Braunschweig, Germany)
were cultured on collagen-coated plates in RPMI 1640 (PAA; Cölbe,
Germany) supplemented with 5% fetal bovine serum (Biochrom; Berlin,
Germany) and 10% horse serum (Biochrom; Berlin, Germany) at 37 °C
and 5% CO2. Transfected cell clones were kept in the presence of
500 μg/ml G418 (Biochrom; Berlin, Germany) to maintain selection.
For cell cycle analyses, cultures were transferred to serum-free medium
for 24 h to stop proliferation. Cell growth was restarted by returning the
cells to normal growth medium supplemented with fetal bovine- and
horse serum, resulting in a synchronized cell cycle [31].
2.2. Plasmids and transfection
cDNA of Map2k4 (GenBank™ Accession Number ID: AY880882.1)
and Map2k4δ (GenBank™ Accession Number ID: KC795688) from
PC12 cells were inserted in the expression vector pEGFP-C3 (Clontech;
Saint-Germain-en-Laye, France) as a BamHI/HindIII fragment. Transfec-
tion of the Map2k4-pEGFP, Map2k4δ-pEGFP constructs or the pEGFP
vector was performed using the Turbofect™ transfection system
(Thermo Fisher Scientiﬁc; St. Leon-Rot, Germany) according to the
manufacturer's instructions. For comparability, stable cell clones with
similar expression levels of the endogenous Map2k4/δ protein and the
Map2k4-pEGFP, Map2k4δ-pEGFP constructs or the pEGFP vector were
chosen. The experiments were performed in at least 3 different cell
clones of each splice variant. Microscopy, cell counts and Western
blots with ﬁve independent stable PC12 clones revealed the same
results.
2.3. Cell counting
Electronic cell counting analyses were performed by CASY® TT cell
counter (Roche Applied Sciences; Mannheim, Germany). An aliquot of
the cell suspension was mixed with CASYton® buffer and cell number
and viabilitywere determined according tomanufacturer's instructions.
The CASY®TT cell counter can determine the complete cell number, the
ratio of cells with damaged cell membrane and themean volume of one
cell.2.4. 5-Bromo-2-deoxyuridine (BrdU) incorporation assay
Cell proliferation was measured using a BrdU incorporation assay
(Roche Applied Sciences; Mannheim, Germany) according to the
manufacturer's instructions. Cells grown in a 96-well-plate were incu-
bated with BrdU for 4 h and ﬁxed. After incubation with an anti-BrdU-
POD-antibody and the subsequent substrate reaction, absorbance was
measured using an ELISA reader (Bio-Rad; München, Germany).
2.5. Whole cell extracts
If not indicated otherwise, chemicals were purchased from Sigma-
Aldrich (Steinheim, Germany) or Carl Roth (Karlsruhe, Germany).
Whole cell lysates were generated from subconﬂuent cells. Before
harvesting, cells were washed with phosphate-buffered saline. For
whole cell extracts, cells were resuspended in denaturing lysis buffer
(20 mM Tris (pH 7.4), 2% SDS, 1% phosphatase inhibitor, and 1%
protease inhibitor), incubated at 95 °C for 5 min, brieﬂy sonicated, and
centrifuged to remove insoluble material (15,000 ×g for 15 min).
2.6. Western blot
Twenty micrograms of total cellular proteins was separated on
10–15% SDS-polyacrylamide gels and transferred to poly-vinylidene
diﬂuoride transfer membranes (Millipore, Schwalbach, Germany). The
membranes were blocked with 4% non-fat dry milk and incubated with
the primary antibodies according to the manufacturer's recommenda-
tions. After three washing steps with TBST, the membranes were incu-
bated with the HRP-conjugated secondary antibody for 30 min. All
Western blotswere developed using the ECL chemiluminescence system
and Hyperﬁlm ECL (GE Healthcare; München, Germany). Between the
stainings with phosphospeciﬁc antibodies and total kinase or total tran-
scription factor antibodies, blots were stripped in 2% SDS, 62.5 mM Tris
and 100 mM 2-mercaptoethanol for 30 min at 50 °C, washed with
TBST and blocked again. All measurements of dual-phosphorylated ki-
nase levels were normalized by hybridization with antibodies against
total kinase protein. To normalize for the protein content of each lane
and to conﬁrm equal loading, all membranes were ﬁnally stained with
Ponceau S. Antibodies against the following targets were purchased
from the indicated sources: mouse IgG (GE Healthcare; München,
Germany); phospho-JNK and phospho-p38 (Promega; Mannheim,
Germany); β-Actin (Sigma-Aldrich; Steinheim, Germany); AKT,
Caspase-8, Caspase-9, cleaved Caspase-3, cleaved Caspase-8, cleaved
Caspase-9, c-Myc, ERK, JNK, Map2k7, MEK1/2, p53, phospho-p53,
phospho-AKT, phospho-ATF-2, phospho-c-Jun, phospho-c-Myc,
phospho-ERK, phospho-Mdm-2, phospho-MEK1/2, phospho-
Map2k4, phospho-Map2k7 and rabbit IgG (New England Biolabs;
Frankfurt, Germany); CyclinD1, JNK1 and Mdm-2 (BD Pharmingen;
Heidelberg, Germany); α-Tubulin, ATF-2, Caspase-3, Fas, Fas-L, JNK2,
Map2k4, p21/WAF1 and p38 (Santa Cruz; Heidelberg, Germany).
2.7. RT-PCR
Total RNAwas isolated fromPC12 cells and tissues usingRNeasy Plus
Kit (Qiagen; Hilden Germany) according tomanufacturer's instructions.
After quantiﬁcation and quality validation, the remaining RNA was
aliquoted and stored at −80 °C. The reverse transcriptase reaction
was performed using the RevertAid™ H Minus First Strand cDNA
Synthesis Kit (Thermo Fisher Scientiﬁc; St. Leon-Rot, Germany) for
RT-PCR according to the manufacturer's instructions with 0.5 μg of
RNA for each sample. The subsequent PCR was carried out with the
DreamTaq™ PCR reagent system (Thermo Fisher Scientiﬁc; St. Leon-
Rot, Germany) by using 0.4–0.6 μl of cDNA, 0.2 mM of each dNTP,
0.2 μM of each primer, and 2.5 units of Taq DNA polymerase. For
normalization, the histone H2A variant H2A.z was used. The absence
of contamination was checked by negative control assays, in which
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pyrocarbonate-treated water or genomic DNA. Ampliﬁcation was per-
formed with the following primer sets: Gapdh_rat: sense 5′-AACGAC
CCCTTCATTGAC-3′, and antisense 5′-TCCACGACATACTCAGCAC-3′;
Gapdh_mouse/human: sense 5′-TCCATGACAACTTTGGTATCGTGG-3′,
and antisense 5′-GACGCCTGCTTCACCACCTTCT-3′; Map2k4_rat: sense
5′ AGGGTAAACGCAAAGCCCT-3′, and antisense 5′-CGTATTCTTTTAAC
TGCCATTATCTG-3′; Map2k4_ mouse/human: sense 5′-AGGGTAAACG
CAAAGCACTG-3′, and antisense 5′-TCAC TACTCCGCATTACTACATCC-
3′;Map2k4δ_rat: sense 5′-GCATGCAGGGCTTTCAGATA-3′, and antisense
5′-ACGAGCTGTCCACTGATGCCGA-3′; Map2k4δ_mouse/human: sense
5′-GCATGCAGGGCTTTCAGATA-3′, and antisense 5′-TCACTACTCCGCAT
TACTACATCC-3′. The speciﬁcity of the primer pairswas veriﬁed by com-
parative alignment using the BLAST database (NCBI, National Institutes
of Health, Bethesda, MD).
2.8. Immunoprecipitation and immunodepletion
For immunoprecipitation (IP) and immunodepletion (ID) native cell
lysates were prepared from subconﬂuent cells. Before harvesting, cells
were washed with phosphate-buffered saline. For whole cell extracts,
cells were resuspended in native lysis buffer (20 mM Tris (pH 7.6),
250mMNaCl, 3mMEDTA, 3mMEGTA, 0.5%Non-Idet P40, 1% phospha-
tase inhibitor, 1% β-glycerolphosphate and 1% protease inhibitor), incu-
bated on ice for 30 min and centrifuged to remove insoluble material
(15,000 ×g for 15 min). One hundred ﬁfty μg of total proteins was used
for IP and ID with the ImmunoCruz™ reagents (Santa Cruz; Heidelberg,
Germany). All steps were performed at 4 °C if not mentioned other-
wise. The samples were precleared for 30 min with the appropriate
preclearing Matrix. The antibody-IP matrix complex was formed by
incubation of 1 μg primary antibody with 50 μl of the appropriate IP
matrix in 500 μl of PBS for 1 h. The IP antibody-IP matrix complex was
washed twice with cold PBS, the pre-cleared sample was mixed with
the antibody-IP matrix complex and incubated overnight. The negative
control was prepared by incubation of the antibody-IP matrix complex
with native lysis buffer. After centrifugation, the supernatants were
collected for Western blots as ID samples, while the pellets containing
immobilized proteins with IP matrix complexes were washed
three times with PBS. The immobilized proteins were dissociated
with 5× reducing electrophoresis buffer in 20 μl of ultra-pure water at
95 °C for 3 min. The supernatants from the dissociation were carefully
loaded onto 12% SDS-gels whereas the matrix was removed by
centrifugation.
2.9. Statistical analyses
All data were obtained from at least 4–5 independent sets of exper-
iments. Statistical analyses were performed with the GraphPrism soft-
ware (www.graphpad.com) using one-way analyses of variance with
repeated measurements.
3. Results
3.1. Identiﬁcation and cloning of a novel Map2k4 splice variant
While amplifying theMap2k4mRNA from rat phaeochromocytoma
PC12 cells, we identiﬁed an additional PCR product. Cloning and se-
quence analyses of both cDNAs revealed two different splice variants
of the transcript. Apart from the expected Map2k4 transcript (11
exons; 1191 bp), we ampliﬁed an apparent splice variant of Map2k4
(12 exons; 1224 bp) including an additional exon (nt 103–135)
(Fig. 1A). This exon contains canonical splice sites and is located be-
tween exon 1 and exon 2. It encodes for an 11 amino acid fragment at
the N-terminus of Map2k4 (Fig. 1B). BLAST-like Alignment Tool (BLAT,
UCSC genome browser) examinations of mouse and human genomeassemblies revealed that it is totally conserved within the Map2k4
genes of all three species. We named the novel gene productMap2k4δ.
To conﬁrm the appearance of the novelMap2k4 splice variant in dif-
ferent tissues from rat, mouse and human, we designed splice variant
speciﬁc primers. Total RNAwas isolated from brain, lung, heart, pancre-
as, kidney, liver and gut sections and transcribed into cDNA. As shown in
Fig. 1C, both splice variants of Map2k4 could be detected in all tissues
from all species, indicating a ubiquitous expression and splicing of
Map2k4.3.2. Characterization of Map2k4- and Map2k4δ-transfected PC12 cells
As the expression analysis in different tissues indicates a general
coexistence of both splice variants, we concluded that the balance
between Map2k4 and Map2k4δmight be important for regular signal
transduction. Therefore, we chose a cell model where both splice
variants could be expressed together, but at different equilibrium condi-
tions. For thus, both cDNAs were cloned into themammalian pEGFP-C3
expression vector and stably transfected Map2k4- andMap2k4δ-PC12
cell lines were generated. We monitored individual clones of both cell
lines with regard to expression levels and activity of exogenous
Map2k4 and Map2k4δ. For further analyses we chose cell clones with
similar protein levels.
Microscopy revealed no morphological differences (data not
shown). Only a strong increase in cell debris was detected in the
Map2k4-transfected cultures. To investigate the growth behavior of
vector-,Map2k4- andMap2k4δ-PC12 cells, electronic cell counts were
carried out. For this purpose, 0.3 × 106 cells were grown on collagen-
coated 6-well plates for 5 days. Transfection with Map2k4 decreased
the number of viable PC12 cells by 35%, while transfection with the
novelMap2k4δ increased cell counts by 40% compared to vector trans-
fection (Fig. 2A).
Subsequently, stable cell clones were screened for protein and acti-
vation levels of the direct Map2k4 substrates, JNK and p38, and their
counterpart Map2k7 by Western blotting. Transfection of PC12 cells
with Map2k4-pEGFP or Map2k4δ-pEGFP increased the overall protein
levels as well as the phosphorylation of Map2k4 compared to vector
controls, while the intracellular protein amount of Map2k7 did not
change (Fig. 2B). However, phosphorylation of Map2k7 was reduced
in Map2k4δ-transfected cells and further decreased by transfection
with Map2k4 compared to vector-transfected PC12 cells. All three cell
lines showed similar levels of JNK1/2 proteins. Activation of JNK1/2, es-
pecially the 54 kDa splice variants, was slightly elevated by transfection
with Map2k4 and Map2k4δ. Looking at the protein amounts of single
JNK isoforms, transfection with Map2k4 and especially with
Map2k4δ increased JNK2-p54 levels compared to control cells,
whereas JNK1 was unaffected. For the second direct Map2k4 sub-
strate p38, no changes could be observed in the amount and phos-
phorylation status (Fig. 2B).
Furthermore, transfection with Map2k4 and Map2k4δ affected
activity and protein levels of p38 and JNK targets. Protein amounts
and phosphorylation of the transcription factor and proto-oncogene
c-Jun were almost unaffected by transfection with Map2k4 compared
to vector-transfected cells but decreased following transfection with
Map2k4δ (Fig. 2B). Interestingly, transfection withMap2k4δ enhanced
phosphorylation of the activating transcription factor 2 (ATF-2) com-
pared to vector- andMap2k4-PC12 cells. The amount of phosphorylated
c-Myc was strongly decreased by Map2k4.
To examine isoform-speciﬁc JNK activity, we performed immuno-
depletion assays, which showed that transfection with Map2k4 in-
creased phosphorylation of JNK2, while overexpression of Map2k4δ
reduced it (Fig. 2C). The phosphorylation of JNK1, however, was only
elevated inMap2k4δ-transfected cells (Fig. 2C).
In summary, exogenous Map2k4 and Map2k4δ changed the activity
of their counterpart Map2k7 and their substrate JNK and thereby affect
Fig. 1. Identiﬁcation of a novelMap2k4 splice variant. (A) Schematic presentation of the exon/intron organization ofMap2k4 andMap2k4δ.Map2k4δ is produced by alternative splicing of
exon 2. The nucleotide sequence of exon 2 is shown under the scheme. (B) Sequence alignment of Map2k4δ (rat), Map2k4 (rat), Map2k4 (mouse) and Map2k4 (human). Differences be-
tween the species are highlighted in gray. (C) Detection ofMap2k4 andMap2k4δ in different tissues from rat, mouse and human. Total RNAwas isolated from tissues and transcribed into
cDNA. Both splice variants were ampliﬁed with speciﬁc primer pairs.
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speciﬁc manner.3.3. Map2k4 and Map2k4δ oppositely inﬂuence cell proliferation
Next we wanted to know if the different quantity of viable cells was
due to changes in proliferation or cell death. We performed 5-bromo-
deoyuridine (BrdU) assays. The transfection with Map2k4 reduced
BrdU incorporation by 20% compared to vector transfected cells, while
Map2k4δ increased BrdU incorporation by 18% (Fig. 3A). These ﬁndingsindicate that an increased expression ofMap2k4 slows cell proliferation,
whereas elevated levels ofMap2k4δ enhance it.
As p21WAF1/Cip1 (p21), CyclinD1 and p53 are important regulators of
cell cycle progression and targets of both, p38 and JNK signaling, we an-
alyzed their protein levels in the three different transfected PC12 cell
lines. Indeed,Map2k4-PC12 cells had increased amounts of p21 protein
and a decreased signal of CyclinD1 compared to vector- andMap2k4δ-
transfected PC12 cells (Fig. 3B). In contrast, Map2k4δ transfection en-
hanced the expression of CyclinD1, p21 levels were not affected. Protein
level of the tumor suppressor p53was increased by transfection of both
Map2k4 variants. However, the expression of the E3 ubiquitin-protein
Fig. 2. Characterization of Map2k4- and Map2kδ-PC12 cells. (A) Effect of Map2k4 and
Map2k4δ on cell growth. Electronical cell counts of vector-, Map2k4- and Map2k4δ-
transfected PC12 cells under normal growth conditions. Vector = 100%. ***/###, p b
0.001 for vector- vs. Map2k4- and Map2k4δ-transfected cells/transfection withMap2k4δ
vs. Map2k4. The data represents ﬁve independent experiments with ternary ascertain-
ment. (B) Effect on activity and protein levels ofMAP2Ks,MAPKs and transcription factors.
Immunoblots of total lysates (20 μg) of vector-,Map2k4- andMap2k4δ-transfected PC12
cells were performed using antibodies against phospho-active forms of MAP2Ks, MAPKs
and transcription factors. Each blot was re-probed with antibodies that recognize total
proteins. (C) Effect on activity levels of JNK isoforms. Single JNK isoforms were
immunodepleted (ID) in native protein extracts (150 μg) from vector-, Map2k4- and
Map2k4δ-transfected PC12 cells. The remaining extracts were ﬁrst immunoblotted with
an antibody against phosphorylated JNK1/2, then stripped and incubated with an
antibody against JNK1/2. Western blots are representative for four independent
experiments.
Fig. 3. Effect ofMap2k4 andMap2k4δ on cell proliferation and basal apoptosis. (A) Effect of
Map2k4 and Map2k4δ on proliferation of PC12 cells. BrdU incorporation assay of vector-,
Map2k4- andMap2k4δ-transfected cells. The cell lines were kept under the same condi-
tions. The data shown represent ﬁve separate experiments with ternary ascertainment.
***/###, p b 0.001 for vector- vs. Map2k4 and Map2k4δ-transfected cells/transfection
with Map2k4δ vs. Map2k4. (B) Protein levels of the cell cycle regulators p21, CyclinD1,
p53 and Mdm-2. Whole cell extracts (20 μg) from vector-, Map2k4- and Map2k4δ-
transfected PC12 cells were immunoblotted against p21, CyclinD1, p53, Mdm-2 and re-
probed with β-Actin antibody. (C) Immunoprecipitations (IP) of native protein extracts
from unstimulated protein extracts of vector-, Map2k4- and Map2k4δ-transfected PC12
cells. ∅, mock, without IP antibody; C, control, lysate. Native protein lysates were
immunoprecipitatedwith an antibody raised against p53 and immunoblottedwith an an-
tibody against Mdm-2. (D) Protein levels of apoptosis regulators. Whole cell extracts were
immunoblotted against Fas, Fas-L and (cleaved) Caspase-3, -8, -9. Western blots are rep-
resentative for four independent experiments.
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inMap2k4δ-PC12 cells. Immunoprecipitations showed that complexes
of p53 and Mdm-2 were slightly reduced following Map2k4δ-
transfection and nearly undetectable following overexpression of
Map2k4 (Fig. 3C).
Another reason for the observed changes in cell viability could be
variations in basal apoptosis. The death receptor Fas is inversely affected
by transfection with the twoMap2k4 splice variants (Fig. 3D). Whereas
Map2k4 caused a reduction of Fas protein level, transfection with
Map2k4δ slightly increased it. The amount of Fas ligand (Fas-L) was un-
affected by Map2k4-overexpression. Surprisingly, effector Caspase-3
was activated by transfection withMap2k4δ and especiallyMap2k4, as
shown by increased cleavage. To analyze if Caspase-3 activation is trig-
gered by extrinsic or intrinsic apoptosis, we monitored cleavage ofinitiator Caspases-8 and -9. While,Map2k4-PC12 cells showed a higher
activation of Caspase-9,Map2k4δ-transfected cells had higher levels of
cleaved Capsase-8 (Fig. 3D).
These ﬁndings indicate that the cell number is regulated via prolifer-
ation and apoptosis: (i) transfection of Map2k4 slowed cell cycle pro-
gression and increased intrinsic apoptosis, resulting in a decreased
number of viable cells; (ii) the novel splice variant Map2k4δ enhanced
proliferation and therebymasked the elevated extrinsic apoptosis, lead-
ing to elevated cell numbers.
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and Map2k4δ
Our results show, that both Map2k4 splice variants have different
effects on kinases, transcription factors and regulators of cell cycle and
apoptosis. As Map2k4 is an activator of two individual signaling
pathways, p38 and JNK, we investigatedMap2k4-splice-variant-speciﬁc
regulation via both mitogen-activated protein kinases.
For deﬁning the role of JNKs and p38 inMap2k4 andMap2k4δ signal
transmission, experiments with the speciﬁc kinase inhibitors SB203580
(SB) or SP600125 (SP)were carried out. Inhibition of JNK reduced phos-
phorylation and protein levels of c-Jun in all three cell lines (Fig. 4). In
contrast, the regulation of the activity of ATF-2, p53 and c-Myc by p38
and JNK is more complex. In control cells, inhibition of p38 or JNK in-
creased activity levels of ATF-2 and reduced phosphorylation of p53.
SP additionally elevated p53protein and c-Myc activity levels. However,
overexpression of Map2k4 reversed the effects of SB and SP on phos-
phorylation of ATF-2. Both compounds decreased the activity levels of
ATF-2. Inhibition of JNK also increased phosphorylated p53 and SB de-
creased expression of p53. InMap2k4δ-transfected PC12 cells inhibition
of p38 and JNK only slightly reduced phosphorylation of p53. Interest-
ingly, SB strongly increased the activity level of c-Myc and both inhibi-
tors slightly increased ATF-2 phosphorylation.
Protein levels of the cell cycle regulator p21WAF/Cip1 were slightly in-
creased by SB and SP in vector transfected PC12 cells but decreased in
Map2k4 and Map2k4δ cells (Fig. 4). CyclinD1, however, was clearly re-
duced by SB and even more by SP in vector controls. Map2k4-
transfected cells only had low CyclinD1 levels, and inhibition of p38
and JNK further decreased it. In Map2k4δ-PC12 cells CyclinD1 protein
levels were only attenuated after JNK inhibition.Fig. 4. Effect of p38 and JNK inhibition on phosphorylation and protein levels of their tar-
gets. Vector-,Map2k4- and Map2k4δ-transfected cells were unstimulated (control; C) or
incubated for 24 h with SB203580 (SB; 5 μM) or SP600125 (SP; 2 μM). Western blots
from whole cell extracts (20 μg) were ﬁrst incubated with antibodies against phospho-
proteins and re-probed with antibodies against total protein. Western blots are represen-
tative for ﬁve independent experiments.Those ﬁndings indicate that bothMap2k4 splice variants affect their
cellular targets via distinct signal ways by p38 and JNK.
3.5. Effects of Map2k4 and Map2k4δ on related signaling pathways
The extracellular signal-regulated kinases (ERKs) 1/2 form the third
group ofmammalianMAPKs and are also implicated in the regulation of
proliferation and cell death. We wanted to ﬁnd out, if up-regulation of
Map2k4 signaling has an impact on activation of ERK1/2 and its activa-
tor MEK1/2. Western blots of unstimulated whole cell extracts showed
that overexpression ofMap2k4 slightly reduced phosphorylation of ERK,
whereasMap2k4δ strongly enhanced it (Fig. 5).
Apart from MAPK signaling, the PI3K/AKT kinase pathway is an im-
portant regulator of survival, proliferation and differentiation in PC12
cells that could interfere with the observed effects of exogenous
Map2k4 and Map2k4δ. Protein levels of AKT were unaffected by
Map2k4 andMap2k4δ (Fig. 5). Interestingly, activation of AKTwas clearly
increased inMap2k4δ-PC12 cells under normal growth conditions.
Taken together,Map2k4 andMap2k4δ not only affect cellular signal-
ing by phosphorylating their direct substrates, p38 and JNK, but also by
crosstalk with ERK and AKT in PC12 cells. Both kinases are strongly
activated inMap2k4δ-PC12 but attenuated byMap2k4.
3.6. Effects of Map2k4 and Map2k4δ on signalosome compositions
Efﬁcient signal transduction is ensured by the formation of protein
complexes, so called signalosomes, built of kinases and their substrates.
As experiments with kinase inhibitors clearly showed differences
between signal pathways of Map2k4- and Map2k4δ-PC12 cells, we
analyzed, if the observed changes are based on altered protein-protein
interactions. Immunoprecipitations demonstrated that the composition
of PC12 cell signalosomes was substantially affected by exogenous ex-
pression ofMap2k4 andMap2k4δ, respectively. Complexes of Map2k4
and JNK1 were reduced in Map2k4 cells and further diminished by
Map2k4δ overexpression (Fig. 6A). Map2k4:JNK2 signalosomes were
also reduced inMap2k4δ-PC12 cells but increased inMap2k4 cells. Inter-
actions between Map2k4 and its second direct substrate p38 were
strongly increased in Map2k4δ-transfected PC12 cells. This suggests
that Map2k4 prefers JNK2 whereas Map2k4δ favors p38 for interaction
and activation. For the second activator of JNK, Map2k7, which showed
decreased activity levels followingMap2k4- andMap2k4δ-transfection
(Fig. 2B), also a diminished complexation could be detected compared
to control cells (Fig. 6B).Fig. 5. Effects of Map2k4 and Map2k4δ on ERK1/2- and AKT-signaling. Immunoblots of
total lysates (20 μg) of unstimulated vector-, Map2k4- and Map2k4δ-transfected PC12
cells were performed using antibodies against phospho-active forms (p-MEK1/2, p-
ERK1/2, p-AKT). Each blot was re-probed with antibodies that recognize total proteins.
Western blots are representative for three independent experiments.
Fig. 6. Effects ofMap2k4 andMap2k4δ on protein–protein interactions. Immunoprecipita-
tions (IP) of native protein extracts from unstimulated protein extracts of vector (V)-,
Map2k4 (4)- andMap2k4δ (4δ)-transfected PC12 cells.∅, mock, without IP antibody; C,
control, lysate. Blots were re-probed with antibodies which recognize the
immunoprecipitated proteins. (A) Native protein lysates were immunoprecipitated with
an antibody raised against Map2k4 and immunoblotted with antibodies against JNK1,
JNK2 and p38. (B) Native protein lysates were immunoprecipitated with an antibody
raised against JNK1/2 and immunoblotted with an antibody against Map2k7. (C) Native
protein lysates were immunoprecipitated with an antibody raised against p38 or JNK
and immunoblottedwith antibodies against p53, ATF-2 and c-Myc.Western blots are rep-
resentative for four independent experiments.
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was altered by the twoMap2k4 splice variants. ATF-2 was preferentially
bound to p38 inMap2k4- andMap2k4δ-PC12 cells, whereas JNK:ATF-2
complexes were primarily found in control cells (Fig. 6C). Association
of p38 and p53 was almost diminished in Map2k4-cells compared to
vector- and Map2k4δ-transfected PC12 cells. The activity of c-Myc was
almost abolished by overexpression ofMap2k4 (Fig. 2C). Indeed, bind-
ing of c-Myc to p38 or JNK could hardly be detected in Map2k4-PC12
cells. InMap2k4δ cells, the amount of p38:c-Myc complexes was nearly
the same as in control cells, but JNK:c-Myc interactions were decreased
as well, possibly explaining the reduced c-Myc phosphorylation com-
pared to controls.
Togetherwith our previous results the followingmodels forMap2k4
and Map2k4δ signaling can be suggested. Map2k4 preferentially acti-
vates JNK2, leading to c-Jun activation and enhanced p21 protein levels
combined with a reduction of CyclinD1 and Fas. This signaling pathwayleads to reduced cell proliferation and increased basal intrinsic apopto-
sis. In contrast, Map2k4δ increasingly binds to p38, which can contrib-
ute to phosphorylation of ATF-2 and increased CyclinD1 and Fas
protein levels. Thereby, Map2k4δ enhances proliferation and sensitizes
the cells to extrinsic apoptosis.
4. Discussion
4.1. Map2k4δ — a novel splice variant of Map2k4
This study presents a novel splice variant ofMap2k4, calledMap2k4δ
and the cellular functions it modulates in concert with Map2k4 in PC12
cells. So far, only one gene product of mammalian Map2k4 genes has
been described.Map2k4δ contains an additional exon of 30 bp. Genome
analyses revealed that this exon is conserved in rat, mouse and human.
Herewe demonstrate thatMap2k4δ is expressed in brains, hearts, lungs,
pancreas, livers, testis and guts of all these species. Thus, both tran-
scripts co-occur and, as Map2k4, Map2k4δ seems to be ubiquitously
expressed. Since the alternative spliced exon is located directly in
front of the region encoding the D-domain, where p38 and JNK bind
to Map2k4 [12], a functional relevance was assumable.
4.2. Map2k4 and Map2k4δ as regulators of proliferation and apoptosis
Both Map2k4 splice variants in naïve PC12 cells affect the growth
behavior of PC12 cells. Whereas Map2k4-overexpression decreased
the number of viable PC12 cells under basal conditions,Map2k4δ trans-
fection increased it. Those changes in cell numbers can be caused by
altered proliferation or cell death. BrdU-assays showed that elevated
expression ofMap2k4 slowed downproliferation,whereasMap2k4δ en-
hanced it. Indeed, Map2k4mediated an increase in p21 protein levels
whereas CyclinD1 levels were down-regulated compared to vector
transfection, which reduces proliferation of PC12 cells [5,6,32].
Our data shows, that up-regulation of p21 in Map2k4 cells is
JNK-dependent. JNKs control p21 expression via p53 [33]. Furthermore,
increased levels of p21 were shown to repress CyclinD1 expres-
sion [34,35]. Transfection with Map2k4δ, however, strongly increased
CyclinD1 expression compared to control PC12 cells and did not affect
the p21 level. Here, an obvious enhancement of ERK and AKT phosphor-
ylationwas found, which could contribute to cell cycle progression [36].
Thus, depending onwhich splice variant predominates, cellular prolifer-
ation is attenuated or elevated. Since cells do not even have to change
the expression of either Map2k4 variant, but just have to modify their
activities by targeting scaffold proteins, activators, phosphatases or
degrading enzymes, keeping Map2k4 and Map2k4δ at just the right
equilibrium enables them to swiftly adapt to different surrounding con-
ditions. This concept of balancing two different Map2k4s might also
help to understand the partly conﬂicting data that exist on the role of
Map2k4. For example, expression of dominant-negativeMap2k4 in em-
bryonic stem cells reduced their proliferation rate [37]. Skin-speciﬁc
knock-out of Map2k4 reduced carcinogen-induced tumorigenesis in
mice [29]. In contrast, Map2k4 is a tumor suppressor in lung adenocar-
cinomas and strongly reduced the number of overt metastasis in a
mouse xenograft model [25]. Of course, even if those contradictory re-
sults were obtained from the same model system, heterogeneity of
cells and experimental conditions are a critical factor. Nevertheless,
our results from the twoMap2k4 splice variants could also account for
the inconsistencies in Map2k4 research so far. As known for variants
of other MAPK, e.g. JNK or p38, Map2k4 should not be considered as a
single, working enzyme that has a deﬁnite role, but rather as a pool of
Map2k4 splice forms that act in concert with other signaling molecules
to fulﬁll certain functions.
Looking at apoptosis regulators, interpretation of our results is not as
clear. Expression of dominant-negativeMap2k4 in embryonic stem cells
reduced constitutive apoptosis [37], but Map2k4 knock-out studies
showed no effect on cell death or even a pro-apoptotic one [28,29,38].
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creased amounts of cleaved Caspase-9 and -3 are detectable. Apparent-
ly, overexpression ofMap2k4 promotes basal apoptosis via the intrinsic
way. In contrast, Map2k4δ-PC12 cells have increased levels of Fas,
cleaved Caspase-8 and -3, indicating extrinsic apoptosis. Therefore,
both Map2k4 variants promote PC12 cell apoptosis under normal cell
growth conditions, which is partially in line with previous ﬁndings
[37]. In Map2k4δ cells, however, enhanced proliferation masks cell
death, slowed cell division of Map2k4 cells further ampliﬁes the de-
creased cell number.4.3. Signal transduction by Map2k4 and Map2k4δ
Map2k4 is unique among all MAP2Ks in its ability to phosphorylate
two different MAPKs, p38 and JNKs. Nevertheless, some studies re-
vealed that theMap2k4 activity towards p38 is less pronounced than to-
wards JNKs. For example, knockout of Map2k4 in MEFs or pancreatic
cancer cells causes a decrease in phospho-JNK levels but not in
phospho-p38 levels under basal or stress conditions [25,39]. Indeed,
overexpression of the Map2k4 splice variants only enhanced JNK1/2
phosphorylation, whereas phophorylated p38 was unaffected. Immu-
noprecipitations show, that Map2k4:JNK2 complexes were mainly
found inMap2k4-transfected PC12 cells. In contrast,Map2k4δ increased
the formation of Map2k4:p38 complexes, while binding of Map2k4 to
JNKs was less detectable. This raises the question why the amount of
phosphorylated p38 is unaffected compared to control cells. One possi-
ble explanation is the increase of activated ATF-2 in Map2k4δ-
transfected cells. ATF-2 can also be phosphorylated via ERK bymitogen-
ic signals and via JNKand p38during stress signaling [40–44]. Therefore,
the enhanced activity of ERK1/2 could account for the increased
phospho-ATF-2 levels in Map2k4δ-cells, which, in turn, limits p38 ki-
nase activity through a negative feedback including transcriptional acti-
vation of MAPK phosphatases [45]. Still, ATF-2 can be associated with
p38 after transfection withMap2k4 andMap2k4δ. The enhanced phos-
phorylation of JNK inMap2k4δ-transfected cells seems to be triggered
byMap2k7, as the activity of Map2k7was increased as well as complex
formation with JNK compared toMap2k4-PC12 cells. Concurrently, the
activity level of Map2k7 was decreased in Map2k4-transfected PC12
cells, which indicates that here the increase of activated JNK1/2 was
due to Map2k4. Likewise, our results suggest that the differentialFig. 7. Cellular signaling of Map2k4 and Map2k4δ. Schematic model of Map2k4- and Map2k4
phosphorylation of p38. Both kinases have opposed effects on AKT- and ERK1/2-signaling, so
an appropriate cell growth.activation of Map2k4 and Map2k7 in the transfected cell lines leads to
the phosphorylation of speciﬁc JNK isoforms: in Map2k4-transfected
cells, JNK2 was activated, while JNK1 phosphorylation predominates
inMap2k4δ-transfected cells.
Surprisingly, phosphorylation of c-Jun was unaffected by Map2k4-
transfection and even reduced followingMap2k4δ-transfection. Studies
on the distribution of Map2k4, JNKs and c-Jun in primary neurons have
shown that Map2k4 and JNKs are mainly located in the cytoplasm,
whereas c-Jun and Map2k7 are mainly located in the nucleus under
basal conditions [46], so that JNKs would be refrained from phosphory-
lating c-Jun. This, in turn, could explain the enhanced ERK1/2 activity,
since c-Jun-mediated gene transcription can be critical to attenuate
ERK activation [47].
Experiments with kinase inhibitors and immunoprecipitations have
shown that both splice variants alter binding and phosphorylation of
transcription factors by p38 and JNK. It is known, that p38 stabilizes
p53, whereas JNK trigger its ubiquitination [48,49]. Map2k4δ increases
complexes of p53 and p38which leads to higher amounts of p53 protein.
Concurrently, binding of p53 toMdm-2 ismore frequently. This ubiquitin
E3-ligase of p53 is a target not only of p38 and JNK, but also of AKTwhich
shows enhanced phosphorylation in Map2k4δ-transfected cells [50].
Thus,Map2k4 is a positive regulator of tumor suppressor p53 but overex-
pression ofMap2k4δ indirectly stimulates its degradation.
Interestingly, exogenous Map2k4 nearly abolished phosphorylation
and protein levels of the c-Myc. The proto-oncogene c-Myc promotes
cell cycle progression, e.g. by repression of p21 [51]. In fact, reduction
of c-Myc is accompanied by high levels of p21 in Map2k4-transfected
cells.
In conclusion, in the present study we have identiﬁed a novel splice
variant ofMap2k4.Map2k4δ is a result of alternative splicing on exon 2
of the Map2k4 gene and it is expressed in various mammalian tissues.
In contrast to the anti-proliferative effect of overexpressed Map2k4,
Map2k4δ drives cell proliferation of PC12 cells. Interestingly, depending
on which Map2k4 splice variant predominates cellular reactions are
considerably different. WhereasMap2k4 promotes the Map2k4-JNK-c-
Jun signal pathway, Map2k4δ-PC12 cells show a preference for
Map2k4-p38-ATF-2 signaling. Placing our results in context of previous
functional studies, Map2k4 alone tightly controls cell proliferation
and would rather be anti-oncogenic. If Map2k4δ signaling prevails
Map2k4, cellular effects of pro-oncogenic ERK1/2 and AKT are promot-
ed (Fig. 7).δ-mediated signaling. Map2k4 preferentially activates JNK, whereas Map2k4δ augments
that a balanced expression and activation of both Map2k4 splice variants is important for
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